Capital Stock (Details Narrative) - USD ($) |
3 Months Ended | 9 Months Ended | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jul. 06, 2026 |
Jun. 26, 2026 |
May 15, 2024 |
Feb. 06, 2023 |
Sep. 23, 2022 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
Jun. 30, 2026 |
Mar. 31, 2026 |
Dec. 31, 2025 |
|
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Gross proceeds | $ 695,890 | $ 1,263,014 | ||||||||||
| Shares issued | 522,876 | |||||||||||
| Shares issued, price per share | $ 7.65 | |||||||||||
| Proceeds from registered direct offering | $ 4,000,001 | $ 4,000,001 | ||||||||||
| Common stock, shares authorized | 300,000,000 | 300,000,000 | 300,000,000 | |||||||||
| Common stock, par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||||||
| Preferred stock, shares authorized | 10,000,000 | 10,000,000 | ||||||||||
| Preferred stock, par value | $ 0.001 | $ 0.001 | ||||||||||
| Common stock, shares issued | 14,114,648 | 14,114,648 | 13,308,985 | |||||||||
| Common stock, shares outstanding | 14,114,648 | 14,114,648 | 13,308,985 | |||||||||
| Preferred stock, shares issued | 0 | 0 | ||||||||||
| Preferred stock, shares outstanding | 0 | 0 | ||||||||||
| Description of terms and conditions in the event of disclosure of mineral products | an aggregate estimate of mineral resources for the Whistler Project or any other project owned or operated by the Company of 3,000,000 additional gold or gold equivalent ounces from the amount reported in the Company’s technical report summary prepared in accordance with S-K 1300 dated September 22, 2022, the lesser of (i) 190,500 Restricted Shares and (ii) the number of Restricted Shares that have not yet become Released Stock at such time (which, as of September 30, 2026, was 158,750 Restricted Shares) will be deemed released as of the date of such Securities Filing, reducing, on a proportional basis, the number of unvested shares of Restricted Shares subject to each vesting condition. | |||||||||||
| Share based compensation expense | $ 292,500 | $ 59,052 | $ 1,149,691 | 354,117 | ||||||||
| Warrants expiration date description | the Company extended the expiration date of its outstanding common stock purchase warrants from April 24, 2026, to May 1, 2026, and further extended the expiration date of the warrants from May 1, 2026, to May 11, 2026, and from May 11, 2026, to May 22, 2026. | |||||||||||
| Recognized as deemed dividends | $ 599,153 | |||||||||||
| 2023 Incentive Plan [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Percentage of shares issued and outstanding | 10.00% | |||||||||||
| Description of vesting of options | The stock options are exercisable for a period of five years from the date of grant and will vest as follows: (a) 25% on the grant date; and (b) 25% on each of the dates that are six, twelve and eighteen months thereafter. | |||||||||||
| Restricted Stock [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Maximum number of shares of common stock may be issued | 1,000,000 | |||||||||||
| Performance based restricted stock granted | 635,000 | 635,000 | ||||||||||
| Restricted shares remain unvested | 158,750 | 158,750 | ||||||||||
| Share based compensation expense | $ 219,534 | 13,621 | $ 651,443 | 9,792 | ||||||||
| Restricted Stock [Member] | Condition One [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Offering description | with respect to 15% of the Restricted Shares, if the Company has not achieved a $250,000,000 market capitalization, based on the number of shares of its outstanding Common Stock multiplied by the volume-weighted average price for any applicable five (5) consecutive trading day period on the principal stock exchange on which its Common Stock is listed prior to the date that is five years after the date of grant of such award | |||||||||||
| Percentage of the restricted shares granted | 15.00% | |||||||||||
| Restricted Stock [Member] | Condition Three [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Percentage of the restricted shares granted | 10.00% | |||||||||||
| Offering description | with respect to 10% of the Restricted Shares, if the Company has not achieved a share price of $25.00 prior to the date that is six years after the date of grant of such award. | |||||||||||
| Share-Based Payment Arrangement, Option [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Intrinsic value of outstanding options | ||||||||||||
| Unrecognized share-based compensation expense | 100,922 | $ 100,922 | ||||||||||
| Weighted-average period for recognition | 6 months 14 days | |||||||||||
| Share-based compensation expenses | $ 55,371 | 48,648 | $ 357,786 | 250,497 | ||||||||
| Restricted Stock Units (RSUs) [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Restricted shares remain unvested | 3,675 | 3,675 | 9,100 | 14,275 | 19,950 | |||||||
| Share-based compensation expenses | $ 17,595 | $ 24,025 | $ 140,462 | $ 113,412 | ||||||||
| Common Stock [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Shares sold | 73,987 | 121,582 | ||||||||||
| Number of exercise warrants | 130,823 | |||||||||||
| Number of shares issued, shares | 15,107 | |||||||||||
| Cashless exercise of warrants | 325,014 | |||||||||||
| Additional Paid-in Capital [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Commissions paid | $ 18,634 | $ 34,968 | ||||||||||
| ATM Program [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Registration, description | the Company entered into an At The Market Offering Agreement (the “Sales Agreement”) with a lead agent and co-agents (collectively, the “sales agents”) providing for an at-the-market equity sales program. The ATM Program and the related prospectus supplement initially permitted the Company to sell newly issued shares of its Common Stock having an aggregate offering price of up to $5.5 million from time to time through the sales agents subject to the terms of the Sales Agreement. On September 30, 2025, and December 12, 2025, the Company filed prospectus supplements with the U.S. Securities and Exchange Commission (the “SEC”) to increase the maximum aggregate offering amount of Common Stock issuable under the ATM Program to $7.6 million and $6.1 million, respectively. | |||||||||||
| Gross proceeds | $ 10,700,000 | |||||||||||
| Fixed cash commission rate | 2.50% | |||||||||||
| ATM Program [Member] | Common Stock [Member] | ||||||||||||
| Subsidiary, Sale of Stock [Line Items] | ||||||||||||
| Issuance of shares | $ 4,200,000 | $ 2,100,000 | ||||||||||